Serum bactericidal activity against 20 strains of Pseudomonas aeruginosa was studied in 10 volunteers after administration of imipenem (25 mg/kg), imipenem (25 mg/kg) plus amikacin (7.5 mg/kg), and ceftazidime (25 mg/kg) plus amikacin (7.5 mg/kg). Eight strains were susceptible and 12 were resistant to ticarciUlin. Serum levels were measured microbiologicaily after 30 Gram-negative bacterial infections are still a major cause of morbidity and death in cancer patients, especially in neutropenic and in burned patients (16). Treatment of these infections often consists of the administration of a broadspectrum P-lactam antibiotic with or without aminoglycoside (6). Imipenem has a broad spectrum of activity against most of the microorganisms responsible for sepsis in granulocytopenic patients (12, 18) and might be considered as a singledrug empiric therapy for these patients (10). The combination of ceftazidime with amikacin is one of the most active regimens for the empiric treatment of febrile granulocytopenic patients, based on in vitro studies (17, 22 Administration of antibiotics. Each volunteer received the following on separate days and by random allocation: imipenem (25 mg/kg), imipenem (25 mg/kg) plus amikacin (7.5 mg/kg), and ceftazidime (25 mg/kg) plus amikacin (7.5 mg/kg). Ceftazidime and amikacin were given by short (15 min) intravenous infusions in 100 ml of 5% dextrose in water; imipenem was infused in 30 min. When combinations were administered, amikacin was infused in the opposite arm and started either 15 min after the beginning of the infusion of imipenem or else simultaneously to the infusion of ceftazidime. Blood samples were taken before and at 30 and 60 min after the start of the infusion of imipenem. For the purpose of comparison, the end of infusion of ceftazidime plus amikacin was considered as time 30 min. The serum was separated from clotted blood and immediately stored (within 1 h after collection) at -80°C until assay. The assays were performed within 3 weeks after collection.
Gram-negative bacterial infections are still a major cause of morbidity and death in cancer patients, especially in neutropenic and in burned patients (16) . Treatment of these infections often consists of the administration of a broadspectrum P-lactam antibiotic with or without aminoglycoside (6) . Imipenem has a broad spectrum of activity against most of the microorganisms responsible for sepsis in granulocytopenic patients (12, 18) and might be considered as a singledrug empiric therapy for these patients (10) . The combination of ceftazidime with amikacin is one of the most active regimens for the empiric treatment of febrile granulocytopenic patients, based on in vitro studies (17, 22 (5) when assaying ceftazidime or imipenem in the presence of amikacin. The influence of SPS on the assay of imipenem and ceftazidime in the presence of amikacin was studied by measuring the recovery of imipenem and ceftazidime in sera spiked with 100, 50, and 25 ,ug/ml in the presence or absence of amikacin (50 ,ug/ml). Each combination was tested three times. For the assay of amikacin, fluorescence polarization immunoassay was used (Abbott Laboratories, Brussels, Belgium) (8, 9) .
Rate of killing in serum. Each serum obtained 30 min after the start of infusion was tested for serum killing rate by the method of Drake et al. (4) . After a 1:2 dilution in supplemented Mueller-Hinton broth (final volume, 2 ml), time-kill curves were started for two strains of P. aeruginosa susceptible to ticarcillin and two strains resistant to ticarcillin. The inoculum concentration was 106 CFU/ml at time zero. All tubes were agitated throughout the experience on a rotator at 37°C. Samples were obtained at time zero and at 1, 2, 4, 6, and 24 h with a 10-j,l calibrated loop. Suitable dilutions were made and plated on Mueller-Hinton agar, and colonies were counted after overnight incubation.
Study of the interaction between imipenem, cilastatin, and ceftazidime when combined with amikacin. The concentrations of imipenem (initial concentrations of 50 and 100 ,ug/ml) with or without cilastatin (50 and 100 jig/ml), with cilastatin alone (50 and 100 jig/ml), or with ceftazidime (50 and 100 ,ug/ml) alone or in combination with amikacin (25 and 50 ,ug/ml) were The serum levels of the three antibiotics are summarized in Table 2 . Significantly lower serum levels of imipenem were obtained 30 min after the start of infusion when the drug was given with amikacin than when imipenem was given alone (Wilcoxon matched-pairs rank test, P ' 0.01). This effect was not observed at 60 min nor did it occur with ceftazidime plus amikacin.
A slight interaction was observed between imipenem and amikacin when they were mixed together in serum,. The decay of imipenem (100 ,ug/ml) in serum was consistent with a single exponential relation: log concentration = slope x (time + constant), in which the slope was -2.15 + 0.07 (mean of three experiments ± standard deviation) and the constant was the log of the initial concentration. In the presence of 25 of ticarcillin-susceptible and -resistant P. aeruginosa is given in Fig. 1 Amikacin in many similar studies has been shown to prevent the emergence of resistant strains (11, 21, 22) .
In conclusion, imipenem alone at a high dose seemed to be promising as single-drug therapy for infections due to P. aeruginosa strains that are either susceptible or resistant to ticarcillin. A significant increase in the rate of killing was observed when amikacin was added to imipenem, although the resulting SBAs were not significantly increased compared with those for imipenem alone, despite the very high dose of imipenem used in the present study.
